The host cell system is a critical determinant of recombinant protein quality and yield, with direct influence on protein ...

The non-viral transfection reagents market presents growth opportunities driven by the demand for cost-effective, low-immunogenicity alternatives to viral vectors, particularly for nucleic acid-based ...

Prestigious European Society for Medical Oncology Conference “trials-in-progress” sessionPivotal OVATION 3 trial of its DNA-mediated ...

In vivo CD19 CAR T-cell therapy showed promising results in a feasibility study of five patients with refractory systemic ...

A major challenge in AAV gene therapy has been developing scalable, cost-efficient processes to reliably produce high-quality vectors.

Despite progress in cancer biology, deciphering the spatial architecture of the tumor microenvironment remains a challenge.

Lonza Group AG has broadened its suite of CGT manufacturing solutions with 2 new products: TheraPEAK AmpliCell Cytokines and ...

Asimov has introduced a new manufacturing platform aimed at improving the scalability and consistency of AAV production for gene therapies.

Polyethyleneimines (PEIs) are extensively researched as non-viral vectors for gene and medication delivery because of their ...

The library was constructed by generating a variety of AAV capsid variants through the insertion of random peptides at a specific site in the capsid. Specifically, a 7-mer peptide display library ...